Abstract:Age is the biggest risk factor for developing most forms of cancer. In breast cancer, over 50% of patients are over 60 years old; however, less than 25% of patients enrolled in clinical trials are in this age bracket. Furthermore, most mouse modeling is performed in young mice, meaning that from preclinical through clinical stages patients ages are not accurately reflected in trials designs. Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with no targeted therapies, so many treatment strategies utilize chemotherapy in combination with immunotherapy – which relies on a functional immune response. It is well known that immune function declines as we age, and thus therapeutic responses may differ with age. It is yet unclear how the tumor immune microenvironment changes with age, and how this may impact therapeutic response. Here, we utilize a mouse model which mimics hallmarks of human immune aging to understand how age impacts TNBC immune responses to dictate disease progression and therapeutic response. Immunologically young (8 weeks old) and aged (∼12 months old) FVB mice were orthotopically injected with syngeneic Met1 TNBC cells. Once tumors became palpable, mice were treated with paclitaxel chemotherapy or vehicle control and/or anti-PDL1 immunotherapy to mimic first-line therapeutic strategies. Tumors grew significantly faster in young control mice compared to aged, but young mice had a more robust response to therapy. Notable, only young mice had a significant benefit of combo therapy over monotherapy alone. Despite aged mice having more circulating CD8+ and CD4+ T cells, tumors in aged mice had significantly more infiltration of CD8+ cytotoxic T cells and FOXP3+ inhibitory T-regulatory cells compared to young control mice, yet only tumors in young mice exhibited an increase in T cell infiltration with therapy. Additionally, the ratio of CD8+ T cells and FOXP3+ Tregs was unchanged with age or treatment. Depletion of either CD8+ or CD4+ T cells led to a complete loss of age-associated differences in tumor growth. RNA sequencing analysis suggests that infiltrating T cells in aged mice may be exhausted due to a chronic interferon (IFN) phenotype, indicated by enrichment of IFN-alpha, IFN-gamma, and IL2 pathways, as well as increased expression of immune exhaustion markers PD1, CTLA4, TIM3 and LAG3. Neutralization of IFN-gamma blocks therapeutic response to anti-PDL1 in young mice but has no impact on aged mice. Analysis of published single cell RNAseq data indicated the same IFN response pathways enriched with age in human TNBC. These results demonstrate that the aging tumor immune microenvironment significantly impacts tumor progression and therapeutic response and suggest that targeting IFN signaling may lead to improved therapeutic responses. Together these findings establish a significant impact of immune aging on TNBC disease progression and response to therapy, highlighting the importance of developing age- stratified treatment strategies to improve responses in patients of all ages. Citation Format: Milos Spasic, Adrienne Parsons, Abigail Recko, Elizabeth Mittendorf, Peter van Galen, Sandra McAllister. Age dictates immune response within the tumor microenvironment of triple negative breast cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer; 2024 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(22_Suppl) nr C016.

Aggressive Mammary Cancers Lacking Lymphocytic Infiltration Arise in Irradiated Mice and Can Be Prevented by Dietary Intervention

Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy

Densely Ionizing Radiation Acts Via The Microenvironment To Promote Aggressive Trp53-Null Mammary Carcinomas

Abstract P5-03-04: Effect of Aging on the Function and Transformation of Murine Mammary Stem Cells

Radiation Acts on the Microenvironment to Affect Breast Carcinogenesis by Distinct Mechanisms That Decrease Cancer Latency and Affect Tumor Type

Irradiation of juvenile, but not adult, mammary gland increases stem cell self-renewal and estrogen receptor negative tumors.

Abstract 4268: Gene Signature of Host Irradiation from Trp53 Null Mammary Tumors Detects Radiation-Preceded Human Cancers and Has Prognostic Value for Sporadic Human Breast Cancer

Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes

Preclinical Evaluation of Radiation Therapy of BRCA1-associated Mammary Tumors Using a Mouse Model

Separate and combined effects of advanced age and obesity on mammary adipose inflammation, immunosuppression and tumor progression in mouse models of triple negative breast cancer

Morphology Dynamics in Intestinal Crypt During Postnatal Development Affect Age-Dependent Susceptibility to Radiation-Induced Intestinal Tumorigenesis in Apc Min/+ Mice: Possible Mechanisms of Radiation Tumorigenesis

Abstract 3326: Low dose radiation alters stromal epithelial interactions to enrich for estrogen receptor(ER)α-negative stem cells and subsequent ER-negative tumors

Mechanisms of Antitumor Activity of Low Doses of Radiation Associated with Activation of Cells’ Defense System

Abstract A011: Assessing pro-tumorigenicity of the aging microenvironment in a murine ovarian cancer model

Senescence-associated tumor growth is promoted by 12-Lipoxygenase

Abstract 3347: Radiation-induced Gastrointestinal (GI) Syndrome As a Function of Age

Different Oncogenes and Reproductive Histories Shape the Progression of Distinct Premalignant Clones in Multistage Mouse Breast Cancer Models

Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine.

Abstract 2304: Biologically distinct mammary tumors develop from Trp53 null tissue transplanted to juvenile versus adult gland.

Reduced High-Dose Radiation-Induced Residual Genotoxic Damage by Induction of Radioadaptive Response and Prophylactic Mild Dietary Restriction in Mice

Abstract C016: Age dictates immune response within the tumor microenvironment of triple negative breast cancer